Kukje Pharma Co., Ltd.

KSE 002720.KS

Kukje Pharma Co., Ltd. Capital Expenditure for the year ending December 31, 2023: USD -803.25 K

Kukje Pharma Co., Ltd. Capital Expenditure is USD -803.25 K for the year ending December 31, 2023, a 20.37% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Kukje Pharma Co., Ltd. Capital Expenditure for the year ending December 31, 2022 was USD -1.01 M, a 38.53% change year over year.
Kukje Pharma Co., Ltd. Capital Expenditure for the year ending December 31, 2021 was USD -1.64 M, a 84.59% change year over year.
Kukje Pharma Co., Ltd. Capital Expenditure for the year ending December 31, 2020 was USD -10.65 M, a -109.85% change year over year.
Kukje Pharma Co., Ltd. Capital Expenditure for the year ending December 31, 2019 was USD -5.07 M, a -64.40% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

KSE: 002720.KS

Kukje Pharma Co., Ltd.

CEO	Tae-hoon Nam
IPO Date	Sept. 29, 2005
Location	South Korea
Headquarters	96-8, Yatap-ro
Employees	247
Sector	Healthcare
Industries Pharmaceuticals Cleaning Supplies Cosmetics Drugstores & Retail Pharmacies Eyewear Personal Care

Description

Kukje Pharma Co., Ltd. engages in manufacturing, importing, exporting, selling, and distributing pharmaceutical products. The company offers pharmaceutical products, including ETC and OTC products, raw materials, intermediates, and side chain products, as well as cosmetics and health care products. Its products include cephalosporins, quinolones, tetracycline, aminoglycosides, macrolides, ophthalmic, antifungal and antiviral agents, ophthalmic agents, adrenal corticosteroids, CNS and osteoporotic agents, antihistamines, NSAIDS and other analgesics, gastrointestinal and cardiovascular agents, antidiabetics, genitourinary and respiratory agents, and other ETC products. The company was founded in 1959 and is headquartered in Seongnam, South Korea.

Key trends

Past 5 years